Format

Send to

Choose Destination
Transl Oncol. 2013 Dec 1;6(6):676-84. eCollection 2013 Dec 1.

EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

Author information

1
MediaPharma srl, Chieti, Italy ; Department of Experimental and Clinical Sciences, G. D'Annunzio University Foundation, Chieti, Italy.
2
Department of Experimental and Clinical Sciences, G. D'Annunzio University Foundation, Chieti, Italy.
3
Department of Experimental and Clinical Sciences, G. D'Annunzio University Foundation, Chieti, Italy ; Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
4
Sigma-Tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy.

Abstract

ErbB-3 (HER-3) receptor is involved in tumor progression and resistance to therapy. Development of specific inhibitors impairing the activity of ErbB-3 is an attractive tool for cancer therapeutics. MP-RM-1, a murine monoclonal antibody targeting human ErbB-3, has shown anticancer activity in preclinical models. With the aim to provide novel candidates for clinical use, we have successfully generated a humanized version of MP-RM-1. The humanized antibody, named EV20, abrogates both ligand-dependent and ligand-independent receptor signaling of several tumor cell types, strongly promotes ErbB-3 down-regulation, and efficiently and rapidly internalizes into tumor cells. Furthermore, treatment with EV20 significantly inhibits growth of xenografts originating from prostatic, ovarian, and pancreatic cancers as well as melanoma in nude mice. In conclusion, we provide a novel candidate for ErbB-3-targeted cancer therapy.

PMID:
24466370
PMCID:
PMC3890702

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center